Cell therapy for knee osteoarthritis. Comparison of treatments with autologous and allogenic mesenchymal stromal cells in a multicenter controlled randomized clinical trial (ARTROCELL).

Resumen del proyecto

The current project, born within the ISCIII Cell Therapy Network (TerCel) and supported by the SCREN platform, proposes a multicenter randomized and controlled study to investigate the therapeutic use of mesenchymal stromal cells (MSC), either autologous or allogeneic, for knee osteoarthritis, a major health problem with unsatisfactory treatments. Our working hypothesis is that the intra-articular injection of the MSC has beneficial effects, which would be obtained by anti-inflammation, modulation of immune function and articular cartilage repair. This proposal is based on evidence obtained both in vitro and in animal experiments, both in the literature and our own experience obtained in preclinical work and in two recently published pilot studies that evidenced efficacy, both for autologous and allogeneic intra-articular treatments with MSC, without adverse effects. Based on the expertise of TerCel and SCREN In the present project we aim to bring this innovative therapy to the clinic. An homogeneous cell product with the same IMPD (from the Valladolid Group-MSV cells-) will be provided by the four Clean Rooms that participate in the project, with the experience of prior trials. This phase II-III, randomized and controlled trial will enrol 120 patients divided into three arms: a) active control (hyaluronic acid), b) autologous MSV, and c) allogeneic MSV. This structure will allow not only to compare each experimental arm to the active control, but also comparing directly autologous and allogeneic cells. The use of allogenic MSV increases the potential and universality of the treatment. Response assessment (1 year and extension to a second one) will be blind and will include the study of the evolution of algofunctional indexes and quality of life, and assessment of cartilage quality by advanced magnetic resonance imaging (T2 mapping relaxation), with a centralized analysis of the results.

Palabras clave

artrosis
medicina regenerativa
terapia celular
células estromales mesenquimatosas
MSC
CEM
médula ósea
alogénico
alogénica
ensayo clínico

Convocatoria

Acción Estratégica en Salud (AES)

Periodo de ejecución

01/01/2019 - 31/12/2022

Investigador Principal

SANCHEZ-GUIJO MARTIN, FERMIN

Centro beneficiario

FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON

Centro de realización

INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANCA (IBSAL)

Comunidad Autónoma

Castilla y León

Provincia

Salamanca

Financiación

767,963 €